Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations

Until recently, estimation of β-amyloid plaque density as a key element for identifying Alzheimer's disease (AD) pathology as the cause of cognitive impairment was only possible at autopsy. Now with amyloid-positron emission tomography (amyloid-PET) neuroimaging, this AD hallmark can be detecte...

Descripción completa

Detalles Bibliográficos
Autores principales: Witte, Michael M., Foster, Norman L., Fleisher, Adam S., Williams, Monique M., Quaid, Kimberly, Wasserman, Michael, Hunt, Gail, Roberts, J. Scott, Rabinovici, Gil D., Levenson, James L., Hake, Ann Marie, Hunter, Craig A., Van Campen, Luann E., Pontecorvo, Michael J., Hochstetler, Helen M., Tabas, Linda B., Trzepacz, Paula T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Neuroimaging
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878065/
https://www.ncbi.nlm.nih.gov/pubmed/27239516
http://dx.doi.org/10.1016/j.dadm.2015.06.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878065/
https://www.ncbi.nlm.nih.gov/pubmed/27239516
http://dx.doi.org/10.1016/j.dadm.2015.06.006

Ejemplares similares